Microchip Technology Inc. vs Mesoblast Limited — how do they compare? Microchip Technology Inc. trades at $82.93 (market cap $43.99B), while Mesoblast Limited trades at $17.03 (market cap $2.21B). The key difference: Microchip Technology Inc. is far larger — about 19.9× Mesoblast Limited's market cap, and Microchip Technology Inc. pays a 2.25% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MCHP | MESO | |
|---|---|---|
Market Cap | $43.99B | $2.21B |
Sector | Technology | Technology |
52-Week High | $102.97 | $20.96 |
52-Week Low | $49.02 | $12.88 |
Enterprise Value | $49.12B | $2.21B |
Dividend Yield | 2.25% | — |
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $81.39, down 3.9% on the day, amid a bullish technical setup and strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.76 exceeding expectations. Recent news highlights robust data center revenue growth (98% last quarter) and strategic acquisitions like Hailo to bolster edge AI capabilities. Valuation metrics remain elevated with a P/E of 119.15, reflecting high growth expectations.
MCHP's outlook is positive with expanding AI infrastructure demand and raised guidance, though high valuation and recent net income pressure in 2025 pose risks. The consensus price target of $104 suggests 28% upside potential. Key risks include execution on growth initiatives and semiconductor cycle volatility. Institutional sentiment remains strongly bullish with no sell ratings among 44 analysts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →